SDF4 Antibody

What is SDF4 and what are its primary cellular functions?

SDF4 (Stromal Cell Derived Factor 4) is a 42-45 kDa calcium-binding protein belonging to the CREC protein family. It contains six EF-hand motifs and calcium-binding domains that play crucial roles in calcium-dependent cellular activities . SDF4 primarily localizes to the Golgi apparatus lumen, with some isoforms also found in the cytoplasm and cell projections .

Current research indicates SDF4 functions in:

• Endoplasmic reticulum (ER) stress response pathways

• Protein folding and quality control

• Cellular calcium homeostasis

• Stress response mechanisms in various pathological conditions

SDF4 has been identified as a potential biomarker in several cancer types, particularly gastric cancer, and plays a role in sepsis prognosis by attenuating ER stress .

Based on manufacturer recommendations across multiple sources, optimal storage conditions for SDF4 antibodies are:

• Store at -20°C for long-term storage

• For short-term storage (≤1 month), 4°C is acceptable

• Aliquot upon receipt to minimize freeze-thaw cycles

• Most formulations contain 50% glycerol and small amounts (0.02-0.05%) of sodium azide or other stabilizers

• Typical buffer systems include PBS at pH 7.2-7.4

Research indicates that SDF4 antibodies maintain stability for approximately 12 months when stored properly and freeze-thaw cycles are minimized .

How can SDF4 antibodies be utilized in cancer biomarker research?

Recent studies have identified SDF4 as a promising diagnostic biomarker for various cancers, particularly gastric cancer. When implementing SDF4 antibodies for cancer biomarker research:

• Serum analysis: A 2023 study demonstrated that serum SDF4 levels distinguished healthy controls from gastric cancer patients with outstanding diagnostic performance (AUC: 0.973, sensitivity: 89%, specificity: 99%), outperforming conventional markers like CEA (AUC: 0.75) and CA19-9 (AUC: 0.639) .

• Tissue expression patterns: Immunohistochemistry using SDF4 antibodies revealed that SDF4 is absent in normal gastric tissues (0% positive staining) but present in the cytoplasm of cancer cells across all stages, with positive staining rates of approximately 66.7% in stage I specimens .

• Correlation with clinical parameters: While serum SDF4 levels showed stage-dependent increases (median levels: 266.2 pg/ml in stage I to 455.1 pg/ml in stage IV), tissue expression measured by IHC did not significantly differ between stages .

• Methodology considerations: Optimal antigen retrieval conditions for IHC include using TE buffer at pH 9.0, with an alternative option of citrate buffer at pH 6.0 .

What role does SDF4 play in endoplasmic reticulum stress, and how can this be studied?

SDF4 has emerged as an important regulator of endoplasmic reticulum (ER) stress, particularly in sepsis pathology:

• Negative regulation of ER stress: Research has demonstrated that SDF4 acts as a negative regulator of ER stress. A 2021 study identified SDF4 as a prognostic factor for 28-day mortality in sepsis patients, where it functions by attenuating ER stress .

• Experimental models: Adenovirus-mediated SDF4 overexpression was shown to attenuate ER stress in cecal ligation and puncture (CLP) mice lung models, providing a research methodology for studying SDF4's role in stress conditions .

• PBMCs analysis: ER stress tends to be more severe in peripheral blood mononuclear cells (PBMCs) from sepsis patients with negative outcomes compared to those with positive outcomes, with SDF4 levels correlating with this phenomenon .

• Recommended approach: Researchers can use SDF4 antibodies in combination with ER stress markers to investigate this relationship, comparing expression patterns in various stress conditions and disease states.

How does SDF4 contribute to angiogenesis and tumor progression?

SDF4 has been identified as a mediator of angiogenesis in response to chemotherapy-induced stress:

• CEBPD/SDF4 axis: Chemotherapy drugs like cisplatin (CDDP) and 5-fluorouracil (5-FU) induce CEBPD expression in fibroblasts, which directly upregulates SDF4 through binding to its promoter (-1004/-569 bp region) .

• Pro-angiogenic effects: SDF4 promotes endothelial cell proliferation, migration, and tube formation. This can be demonstrated using:

  • Conditioned medium from drug-stimulated fibroblasts

  • Purified recombinant SDF4 protein

  • Matrigel plug assays showing increased hemoglobin content in SDF4-treated plugs

• CXCR4 receptor interaction: SDF4 interacts with CXCR4 receptors on endothelial cells, which can be verified through:

  • Co-immunoprecipitation with membrane fractions

  • Immunofluorescence colocalization studies

  • Functional inhibition using the CXCR4 antagonist AMD3100

• Experimental verification: In vivo studies using xenograft models showed that tumors cotransplanted with SDF4-expressing fibroblasts exhibited higher CD31 expression (an angiogenesis marker) and increased metastasis following chemotherapy treatment .

What are the optimal antigen retrieval conditions for SDF4 immunohistochemistry?

For successful SDF4 immunohistochemistry in various tissue types:

• Primary buffer recommendation: TE buffer at pH 9.0 is suggested as the primary antigen retrieval solution for optimal SDF4 detection .

• Alternative method: Citrate buffer at pH 6.0 can serve as an alternative when TE buffer is unavailable or ineffective in certain tissue types .

• Validated tissues: Successful SDF4 immunodetection has been confirmed in:

  • Mouse testis tissue

  • Human pancreas tissue

  • Human colon tissue

  • Human esophageal cancer

  • Human thyroid cancer

• Recommended dilutions: For IHC applications, dilution ranges from 1:50-1:500 have been validated, with some protocols suggesting more specific ranges (1:30-1:150) .

• Optimization note: The ideal dilution should be determined empirically for each specific tissue type and experimental condition .

What methods are most effective for measuring SDF4 protein levels in clinical samples?

For quantitative assessment of SDF4 protein levels in clinical specimens:

• Serum analysis: ELISA has proven highly effective for measuring serum SDF4 levels, with studies establishing:

  • Normal range in healthy controls: median 83.8 pg/ml (range 17.9-169.9 pg/ml)

  • Diagnostic cutoff for gastric cancer: 164 pg/ml (89% sensitivity, 99% specificity)

  • Stage-dependent increases in median values from 266.2 pg/ml in stage I to 455.1 pg/ml in stage IV

• Tissue expression: Immunohistochemistry provides valuable qualitative and semi-quantitative assessment of SDF4 expression patterns:

  • Positive staining typically appears in the cytoplasm of cancer cells

  • Both mucosal side and invasive front show positive staining in SDF4-positive tumors

  • Positive staining rates do not significantly differ between cancer stages

• Cell line analysis: For in vitro studies, measuring both intracellular and secreted SDF4 is recommended:

  • Cell lysates and conditioned media can be analyzed by ELISA

  • A significant correlation has been observed between intracellular and secreted levels (Spearman's correlation coefficient 0.736, P = 0.015)

How should researchers validate SDF4 antibody specificity?

To ensure experimental rigor and reproducibility when working with SDF4 antibodies:

• Positive control tissues/cells: Use validated positive controls including:

  • Mouse brain tissue

  • DU145 cells

  • Human pancreas tissue

  • Human colon tissue

• Blocking peptide validation: For applications where non-specific binding is a concern:

  • Use blocking peptides corresponding to the antibody's immunogen

  • Compare staining patterns between blocked and unblocked antibody

  • Specific binding will be absent in experiments using the neutralized antibody

• Western blot verification: Confirm antibody specificity by Western blot, looking for a single band at the expected molecular weight of approximately 42-45 kDa

• Cross-reactivity testing: When working across species, verify reactivity as documented antibodies have confirmed:

  • Human reactivity

  • Mouse reactivity

  • Rat reactivity (in some antibodies)

What are the recommended protocols for studying SDF4-CXCR4 interactions?

Recent research has identified that SDF4 can interact with the CXCR4 receptor, traditionally known as the receptor for SDF1. To study this interaction:

• Co-immunoprecipitation: The interaction between SDF4 and CXCR4 can be demonstrated by:

  • Incubating recombinant SDF4 protein with membrane fractions of HUVEC lysates

  • Immunoprecipitating with anti-SDF4 or anti-CXCR4 antibodies

  • Detecting the binding partner by Western blot

• Immunofluorescence colocalization:

  • Treat cells with purified recombinant SDF4

  • Perform double immunofluorescence staining for SDF4 and CXCR4

  • Analyze colocalization using confocal microscopy

• Functional validation:

  • Use CXCR4 antagonists (e.g., AMD3100) to block SDF4-induced effects

  • Measure functional endpoints such as proliferation, migration, or tube formation

  • Compare results with SDF4 treatment alone versus SDF4 + antagonist

• Receptor binding assays:

  • Use labeled SDF4 (fluorescent or radioactive) to measure direct binding to cells expressing CXCR4

  • Determine binding parameters through competitive displacement assays

What are common issues when using SDF4 antibodies and how can they be addressed?

When working with SDF4 antibodies, researchers may encounter several technical challenges:

• Variable signal intensity in IHC:

  • Problem: Inconsistent staining across different tissues

  • Solution: Optimize antigen retrieval method; TE buffer at pH 9.0 is recommended as primary choice, with citrate buffer at pH 6.0 as an alternative

  • Approach: Titrate antibody concentration within the recommended range (1:30-1:500 depending on application)

• Background in Western blots:

  • Problem: Non-specific bands or high background

  • Solution: Optimize blocking conditions (3% nonfat dry milk in TBST has been validated)

  • Approach: Use appropriate antibody dilution (1:1000 for WB has shown clean results) and consider blocking peptide validation

• Storage-related loss of activity:

  • Problem: Diminished signal after storage

  • Solution: Store in aliquots at -20°C with 50% glycerol to prevent freeze-thaw damage

  • Approach: Avoid repeated freeze/thaw cycles; for short-term use, store at 4°C

• Cross-reactivity concerns:

  • Problem: Uncertain specificity across species

  • Solution: Verify reactivity in your species of interest; well-validated for human and mouse samples

  • Approach: Include proper positive and negative controls for each experiment

How can researchers determine the optimal antibody concentration for different experimental systems?

Determining the ideal antibody concentration requires systematic optimization:

• Application-specific titration ranges:

• Titration strategy:

  • Begin with the manufacturer's recommended dilution range

  • Perform a dilution series using 2-3 fold increments

  • Test on known positive samples (e.g., mouse brain, human pancreas)

  • Select the dilution that provides optimal signal-to-noise ratio

• System-specific optimization:

  • For IHC: Test both TE buffer (pH 9.0) and citrate buffer (pH 6.0) antigen retrieval methods

  • For WB: Optimize protein loading (25 μg/lane has been validated)

  • For all applications: "Sample-dependent, check data in validation data gallery"

• Quality control measures:

  • Include known positive and negative controls in each experiment

  • Document optimization parameters for reproducibility

  • Consider lot-to-lot validation when receiving new antibody

How can SDF4 antibodies be used to investigate its role in cancer progression and therapy response?

SDF4 antibodies enable multiple research approaches to understand cancer biology:

What experimental approaches can be used to study SDF4's function in stress response pathways?

SDF4 plays important roles in cellular stress responses, particularly ER stress, which can be investigated through:

• Gene expression modulation:

  • Overexpression: Adenovirus-mediated SDF4 overexpression has been shown to attenuate ER stress in animal models

  • Knockdown: siRNA or CRISPR-based approaches to reduce SDF4 expression and observe effects on stress markers

  • Monitoring approach: Use SDF4 antibodies to confirm expression changes by Western blot or IHC

• Stress induction models:

  • Sepsis models: Cecal ligation and puncture (CLP) in mice has been used to study SDF4's role in sepsis

  • ER stress inducers: Tunicamycin, thapsigargin, or other ER stress-inducing agents

  • Chemotherapy drugs: CDDP and 5-FU induce stress responses in fibroblasts that upregulate SDF4

• Stress marker correlation:

  • Compare SDF4 expression with established ER stress markers

  • Analyze whether SDF4 expression changes precede or follow other stress responses

  • Use dual staining approaches with SDF4 antibodies and stress marker antibodies

• Clinical correlation:

  • Analyze SDF4 expression in patient samples under various stress conditions

  • Research has shown that SDF4 is associated with 28-day mortality in sepsis patients

  • Build predictive models incorporating SDF4 expression data (one model achieved AUC=0.908)

What emerging applications of SDF4 antibodies show promise for translational research?

Several innovative applications of SDF4 antibodies are emerging with potential clinical impact:

• Liquid biopsy development:

  • SDF4 has been identified as a promising liquid biopsy-based diagnostic marker for gastric cancer

  • Serum SDF4 levels can distinguish healthy controls from early-stage cancer patients with high sensitivity and specificity

  • Further validation studies could establish SDF4 as a non-invasive screening tool for multiple cancer types

• Therapeutic response monitoring:

  • The relationship between SDF4 and angiogenesis suggests potential applications in monitoring anti-angiogenic therapy efficacy

  • SDF4 antibodies could help identify patients likely to benefit from such treatments

  • Serial measurements might predict treatment resistance or recurrence

• Prognostic modeling in critical illness:

  • SDF4's role in sepsis mortality prediction (AUC=0.908) suggests applications in critical care

  • Integration with other biomarkers could improve patient stratification

  • Interventions targeting the SDF4 pathway might improve outcomes in sepsis

• Drug target validation:

  • As research concludes that "SDF4 can be a therapeutic target in inhibition of angiogenesis for chemotherapy drug-administrated cancer patients"

  • Antibodies that neutralize SDF4 function could have therapeutic potential

  • Combination strategies targeting both SDF4 and its receptor CXCR4 might overcome resistance